Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Manganese in children with attention-deficit/hyperactivity disorder: relationship with methylphenidate exposure.

Farias AC, Cunha A, Benko CR, McCracken JT, Costa MT, Farias LG, Cordeiro ML.

J Child Adolesc Psychopharmacol. 2010 Apr;20(2):113-8. doi: 10.1089/cap.2009.0073.

PMID:
20415606
2.
3.

Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.

Cohen-Yavin I, Yoran-Hegesh R, Strous RD, Kotler M, Weizman A, Spivak B.

Clin Neuropharmacol. 2009 Jul-Aug;32(4):179-82. doi: 10.1097/WNF.0b013e318183796d.

PMID:
19644227
4.

A pilot study: differential effects of methylphenidate-OROS on working memory and attention functions in children with attention-deficit/hyperactivity disorder with and without behavioural comorbidities.

Rubio B, Hernández S, Verche E, Martín R, González-Pérez P.

Atten Defic Hyperact Disord. 2011 Mar;3(1):13-20. doi: 10.1007/s12402-010-0035-x. Epub 2010 Oct 21.

PMID:
21432614
5.

Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.

Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.

Curr Med Res Opin. 2014 Aug;30(8):1673-85. doi: 10.1185/03007995.2014.904772. Epub 2014 Apr 15. Review.

PMID:
24627974
6.

No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.

Walitza S, Kämpf K, Artamonov N, Romanos M, Gnana Oli R, Wirth S, Warnke A, Gerlach M, Stopper H.

Toxicol Lett. 2009 Jan 10;184(1):38-43. doi: 10.1016/j.toxlet.2008.10.011. Epub 2008 Oct 28.

PMID:
19015014
7.

Molecular imaging genetics of methylphenidate response in ADHD and substance use comorbidity.

Szobot CM, Roman T, Hutz MH, Genro JP, Shih MC, Hoexter MQ, Júnior N, Pechansky F, Bressan RA, Rohde LA.

Synapse. 2011 Feb;65(2):154-9. doi: 10.1002/syn.20829.

PMID:
20593420
8.

Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task.

Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, Taylor E.

Neuropharmacology. 2009 Dec;57(7-8):640-52. doi: 10.1016/j.neuropharm.2009.08.013. Epub 2009 Aug 26.

PMID:
19715709
9.

Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths.

Leddy JJ, Waxmonsky JG, Salis RJ, Paluch RA, Gnagy EM, Mahaney P, Erbe R, Pelham WE, Epstein LH.

J Child Adolesc Psychopharmacol. 2009 Apr;19(2):127-36. doi: 10.1089/cap.2008.046.

PMID:
19364291
10.

Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.

Markowitz JS, Straughn AB, Patrick KS.

Pharmacotherapy. 2003 Oct;23(10):1281-99. Review.

PMID:
14594346
11.
12.

Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.

Cho SC, Kim BN, Cummins TD, Kim JW, Bellgrove MA.

J Psychopharmacol. 2012 Mar;26(3):380-9. doi: 10.1177/0269881111405356. Epub 2011 May 31.

PMID:
21628343
13.

Differential effects of methylphenidate and atomoxetine on attentional processes in children with ADHD: an event-related potential study using the Attention Network Test.

Kratz O, Studer P, Baack J, Malcherek S, Erbe K, Moll GH, Heinrich H.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):81-9. doi: 10.1016/j.pnpbp.2011.12.008. Epub 2011 Dec 29.

PMID:
22227291
14.

Methylphenidate improves some but not all measures of attention, as measured by the TEA-Ch in medication-naïve children with ADHD.

Paton K, Hammond P, Barry E, Fitzgerald M, McNicholas F, Kirley A, Robertson IH, Bellgrove MA, Gill M, Johnson KA.

Child Neuropsychol. 2014;20(3):303-18. doi: 10.1080/09297049.2013.790358. Epub 2013 May 2.

PMID:
23639119
15.

Pharmacogenetics of response to methylphenidate in adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD): a systematic review.

Contini V, Rovaris DL, Victor MM, Grevet EH, Rohde LA, Bau CH.

Eur Neuropsychopharmacol. 2013 Jun;23(6):555-60. doi: 10.1016/j.euroneuro.2012.05.006. Epub 2012 Jun 17. Review.

PMID:
22709890
16.

Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.

Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.

Psychiatry Clin Neurosci. 2009 Apr;63(2):167-75. doi: 10.1111/j.1440-1819.2009.01937.x.

17.

Dopamine transporter genotype influences the physiological response to medication in ADHD.

Gilbert DL, Wang Z, Sallee FR, Ridel KR, Merhar S, Zhang J, Lipps TD, White C, Badreldin N, Wassermann EM.

Brain. 2006 Aug;129(Pt 8):2038-46. Epub 2006 Jun 7.

PMID:
16760197
18.

MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder.

Schweren LJ, de Zeeuw P, Durston S.

Eur Neuropsychopharmacol. 2013 Oct;23(10):1151-64. doi: 10.1016/j.euroneuro.2012.10.014. Epub 2012 Nov 17. Review.

PMID:
23165220
19.

Effects of methylphenidate on olfaction and frontal and temporal brain oxygenation in children with ADHD.

Schecklmann M, Schaldecker M, Aucktor S, Brast J, Kirchgässner K, Mühlberger A, Warnke A, Gerlach M, Fallgatter AJ, Romanos M.

J Psychiatr Res. 2011 Nov;45(11):1463-70. doi: 10.1016/j.jpsychires.2011.05.011.

PMID:
21689828
20.

Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.

Zheng Y, Wang YF, Qin J, Wang LW, Zou LP, Jin XM, Xu T, Wang Y, Qi YL, Gong ME, Yin QY, Mai JN, Jing J, Luo XY, Ma HW, Li HB, Xie L, Li Y, Kuang GF, Yi MJ, Wang F, Zhu XH, Yao YB.

Chin Med J (Engl). 2011 Oct;124(20):3269-74.

PMID:
22088519

Supplemental Content

Support Center